MetAlert, Inc. (MLRT) Recognizes Link Between Cognition in Aging Population and Use of Hearing Aids

• MetAlert has, since its inception, sought to offer quality-of-life improvements to patients and caregivers dealing with Alzheimer’s, dementia, and autism (“ADA”)
• This focus has led to the company offering products and services within the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring
• Also important is MetAlert’s offering of hearing aids, ranging from its flagship Hear IQ 4 rechargeable, app-controlled hearing aid, the NRBz noise-reducing buds, HearingVite, and the Ear-Ring Relief formula
• MetAlert understands the correlation between cognitive decline and hearing loss, with persons with hearing loss who wore devices performing better on cognitive scores in the short term, according to a study published on December 5, 2022
• The company is optimistic that, as the conversation around ADA progresses, more people will start seeking early diagnosis and treatment for cognitive decline and embrace the use of hearing aids as one step to preserve cognition

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, has, since its inception, sought to offer quality of life improvements to patients and consumers who have Alzheimer’s, dementia and autism (“ADA”). This focus has yielded the design, development, manufacturing, distribution, and sale of products and services within the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. All these offerings have been well-received and have proven to offer value to those afflicted with ADA.

Its flagship product, GPS SmartSoles HUB, launched in the fourth quarter of the 2022 financial year, allows for remote monitoring, data collection, and encrypted data transmission to the cloud. In addition, RoomMate, MetAlert’s latest offering, allows caregivers to monitor patient behavior that could lead to falls and injuries without invading their privacy. As evidenced by these two products, MetAlert prioritizes patient confidentiality while pushing the needle regarding the use of technology to improve service delivery and the quality of life of patients afflicted with ADA.

The focus on this target population has also seen MetAlert offer hearing aids, ranging from its flagship Hear IQ 4 rechargeable, app-controlled hearing aid to the NRBz noise-reducing buds. The company also offers HearingVite, a formulation proven to boost memory and cognitive function among individuals aged 50 years and above. It also offers Ear-Ring Relief, a formula that integrates vitamins, minerals, and nutritional supplements to relieve Tinnitus sufferers (https://ibn.fm/AgbFE).

MetAlert understands the correlation between cognitive decline and hearing loss, hence its foray into developing and delivering hearing aids and accompanying formulations. A study published on December 5, 2022, noted that people with hearing loss who wore devices to help performed 3% better on cognitive scores in the short term. The study further established that the use of hearing aids was associated with a 19% reduction in long-term cognitive decline, making it a viable option for preventing the onset of dementia (https://ibn.fm/niT1g).

“Encouragingly, even patients who already started with mild cognitive impairment (‘early dementia’) in our pooled analysis also benefitted from the use of hearing aids, as they also had approximately 20% lower risk of progressing to dementia,” noted Dr. Benjamin Tan, Dean’s Fellow at the Yong Loo Lin School of Medicine, National University of Singapore.

“This means that it is never too late to start using hearing aids, but early treatment may help preserve the most cognition,” he added.

Hearing aids are not the only way to prevent cognitive decline. As such, MetAlert advocates for a well-rounded, preventive approach that includes a healthy diet, vigorous physical activity, good sleep, stress reduction, and an active social life. With persons afflicted with ADA accounting for 2.9% of the world’s population or about 34 million individuals in 24 developed countries, the company understands the severity of the situation and is committed to offering solutions specific to the needs of these individuals.

MetAlert’s management is optimistic that as the conversation around ADA progresses, more people will start seeking early diagnosis and treatment for cognitive decline and embrace the use of hearing aids to preserve cognition. The World Health Organization (“WHO”) estimates that by 2050, the proportion of older people will have increased to about 139 million, which will also see an increase in individuals living with ADA (https://ibn.fm/dAq4k). MetAlert hopes that early diagnosis and the use of hearing aids will help reduce these numbers while improving the lives of those who may develop these conditions over time.

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.